This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
A U.S. radiological study suggests preventing lung scarring during radiation therapy for lung cancer might extend patients' lives. Researchers at New York University Medical Center have found that using a special type of drug called a pharmaceutical monoclonal antibody to prevent a serious side effect of radiation therapy for lung cancer patients -- pulmonary fibrosis, or scarring of the lungs -- extends patients' lives and improves their quality of life.
We care about your feedback. Let us know how we can improve your CancerCompass experience.